Business
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
IBSRELA®(tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in AdultsFirst Novel Mechanism Therapy to Treat IBS-C in a
About this update from Ardelyx, Inc.
[{"type":"text","content":"IBSRELA®(tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in AdultsFirst Novel Mechanism Therapy to Treat IBS-C in a DecadeProduct Now AvailableWALTHAM, Mass., April 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is the first FDA-approved product for Ardelyx.\n\n \n \n \n \n \n \n\n \n\"The commercialization of IBSRELA marks a significant milestone for Ardelyx and for adult patients with IBS-C and their healthcare providers,\" said Mike Raab, president and chief executive officer of Ardelyx. \"It's hugely rewarding to see an idea born from our discovery research translate into a breakthrough medicine for patients. IBSRELA is the first novel mechanism therapy to be introduced for IBS-C in over a decade and offers an important new option to treat the abdominal pain, bloating, and discomfort, along with the constipation associated with this debilitating condition. We have built a world-class commercial team and are entering the market with a highly experienced sales force, a disruptive omnichannel approach, and an innovative and differentiated therapy that meets a significant unmet need.\"\nAnthony Lembo, M.D., director of the GI Motility and Functional Bowel Disorders Program at Beth Israel Deaconess Medical Center and professor of medicine at Harvard Medical School, added, \"Innovative, novel therapies are needed in IBS-C due to the heterogeneous nature of the condition and the large proportion of patients who continue to suffer despite treatment. The launch of IBSRELA, a first-in-class NHE3 inhibitor, provides a new treatment option with a novel mechanism of action and impressive efficacy data to address the constipation and multiple abdominal symptoms commonly seen in patients with IBS-C, as demonstrated in the Phase 3 clinical trials. I am excited to have a new treatment option that offers the potential to advance the care of patients who suffer from IBS-C.\"\nThe approval of IBSRELA is based on two successful Phase 3 trials involving over 1,200 patients ...